Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05462314 | Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies | completed | — | 24 | ViomeINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 |
| clinicaltrials |
| NCT06249841 | Feasibility of Cryobiopsy from the Bile Duct - CRYLEO(CRYLEO) | completed | N/A | 15 | Erbe Elektromedizin GmbHINDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06776185 | Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma | completed | — | 3,000 | Chen XiaopingOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06775158 | Perioperative Myocardial and Renal Injury in Patients Undergoing Hepatic Resection | completed | — | 128 | Istanbul Saglik Bilimleri UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04272619 | Liver Cancer Community Education | completed | N/A | 67 | Fox Chase Cancer CenterOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760494 | Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability(MAPUSE) | completed | — | 250 | Chinese PLA General HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03756051 | Harms of Hepatocellular Carcinoma Surveillance | completed | — | 2,871 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04802954 | Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients(STARHE) | completed | N/A | 400 | IHU StrasbourgOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03999593 | Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma | completed | — | 60 | University of LiverpoolOTHER | 0 | Dec 17, 2024 | clinicaltrials |
| NCT01640522 | Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms(CaSSY) | completed | N/A | 261 | University of PittsburghOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT00410956 | Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02528643 | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 165 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Dec 6, 2024 | clinicaltrials |
| NCT01210027 | A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion | completed | — | 143 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06683820 | Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques | completed | — | 3 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03009461 | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | completed | Phase 2 | 64 | Peking UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04926376 | Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC) | completed | N/A | 8 | ABK BiomedicalINDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06290739 | A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma | completed | — | 483 | West China HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04860154 | Photodynamic Therapy for Cholangiocarcinoma | completed | N/A | 86 | Hepatopancreatobiliary Surgery Institute of Gansu ProvinceOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT00059267 | Prevention of Recurrent Hepatitis B After Liver Transplantation | completed | — | 317 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03268499 | Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma | completed | N/A | 80 | Chinese University of Hong KongOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | completed | Phase 2 | 25 | NovoCure Ltd.INDUSTRY | 6 | Nov 14, 2024 | clinicaltrials |
| NCT04313868 | GEN2 Directed Cancer Immunotherapy Trial(GEN2) | completed | Phase 1 | 61 | GenVivo, Inc.INDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04740164 | A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP | completed | N/A | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05003700 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 39 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT00607828 | Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer | completed | N/A | 7 | University of NebraskaOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04954794 | TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) | completed | Phase 2 | 29 | Fudan UniversityOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06663904 | Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis(AMRI; LIRADS) | completed | — | 938 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | completed | Phase 2 | 249 | BeiGeneINDUSTRY | 8 | Oct 26, 2024 | clinicaltrials |
| NCT02511522 | Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases | completed | N/A | 66 | Canadian Cancer Trials GroupNETWORK | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT06637059 | Artificially Intelligent Model for Accurate Detection of HCC | completed | — | 1,092 | Zhejiang UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04011033 | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | completed | Phase 2 | 60 | Beijing YouAn HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06629857 | A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan | completed | — | 94 | Darul Sehat HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06631352 | Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy(HPD_single) | completed | — | 50 | Seoul National University HospitalOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT03253289 | Meclizine for Hepatocellular Carcinoma(OPTIM) | completed | Phase 1 | 13 | Tannaz ArmaghnayOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06621485 | Calculator Predicts Early Mortality Post Hepatocellular Carcinoma Resection | completed | — | 4,966 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2025source: clinicaltrials